PMID: 9159135May 27, 1997Paper

Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor

Proceedings of the National Academy of Sciences of the United States of America
M NikiT Noda

Abstract

The Pebpb2 gene encodes a non-DNA binding subunit of the heterodimeric transcription factor, polyomavirus enhancer binding protein 2/core binding factor (PEBP2/CBF), and is rearranged in inversion of chromosome 16 associated with human acute myeloid leukemia. To investigate its physiological function, Pebpb2 was mutated by a targeting strategy to generate a null mutant. The homozygous mutation in mice proved lethal in embryos around embryonic day 12.5, apparently due to massive hemorrhaging in the central nervous system. In addition, definitive hematopoiesis in the liver was severely impaired. The observed phenotype was indistinguishable from that reported for homozygous disruption of AML1, which encodes a DNA binding subunit of PEBP2/CBF. Thus, the results indicate that the two subunits function together as a heterodimeric PEBP2/CBF in vivo and that PEBP2/CBF plays an essential role in the development of definitive hematopoiesis.

References

Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H MiyoshiM Ohki
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·T R GolubD G Gilliland
Mar 10, 1995·The Journal of Biological Chemistry·S H Orkin
Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·V E Valge-ArcherT H Rabbitts
Apr 1, 1994·Molecular and Cellular Biology·C E DabrowskiP A Schaffer
Oct 1, 1993·Trends in Genetics : TIG·H KagoshimaP Gergen
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·E OgawaY Ito
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·Q WangN A Speck
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·K SasakiT Komori

❮ Previous
Next ❯

Citations

Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·Chouhei SakakuraYoshiaki Ito
Jun 9, 2001·Biochemical and Biophysical Research Communications·Y HaradaA Kimura
Nov 28, 2001·International Journal of Hematology·T OkudaY Fujita
Jul 4, 2002·International Journal of Hematology·Alan D Friedman
Jan 29, 2008·International Journal of Hematology·Hitoshi Yoshida, Issay Kitabayashi
Jul 3, 2008·International Journal of Hematology·Tomomasa YokomizoYoshiaki Ito
Oct 17, 2001·Developmental and Comparative Immunology·D R Barreda, M Belosevic
Aug 26, 2003·Journal of Autoimmunity·Marta E Alarcón-Riquelme, Ludmila Prokunina
Mar 1, 2002·Current Opinion in Immunology·Kam-Wing Ling, Elaine Dzierzak
Nov 8, 2001·Current Opinion in Cell Biology·S I Nishikawa
Nov 16, 2002·Nature Genetics·Carolina A YoshidaToshihisa Komori
Jan 5, 2000·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Y Ito
Aug 9, 2008·The Journal of Biological Chemistry·Yusuke SatohYuzuru Kanakura
Jan 19, 2000·The Journal of Experimental Medicine·K MurataK Sugamura
Sep 19, 2001·Current Opinion in Hematology·M Kundu, P P Liu
May 17, 2006·Genes & Development·Takuo KatsumotoIssay Kitabayashi
Apr 25, 2002·Molecular and Cellular Biology·Hitoshi OkadaTak W Mak
Oct 11, 2013·Endocrine-related Cancer·Rosalinda M Savoy, Paramita M Ghosh
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·B LutterbachS W Hiebert
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·G M CuencoR Ren
Feb 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·James C MulloyStephen D Nimer
Mar 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·L H CastillaP P Liu
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·S C KoganJ M Bishop
Sep 1, 1997·Trends in Genetics : TIG·A V Anagnostopoulos
Aug 25, 2004·Biochemical and Biophysical Research Communications·Hisako GunjiKinuko Mitani
Feb 17, 2006·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Karine BollerotThierry Jaffredo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.